STAT1

Signal transducer and activator of transcription 1 (STAT1) is a critical transcription factor that mediates cellular responses to interferons and cytokines by undergoing tyrosine phosphorylation, dimerization, and nuclear translocation to regulate target gene expression^[1][2]. Mechanistically, STAT1 modulates the JAK/STAT signaling pathway, influencing immune regulation, apoptosis, and inflammation, and it can inhibit the Ras-MAPK pathway and Rho GTPase expression, thereby controlling cell proliferation and adhesion^[3]. STAT1 exists as functionally distinct α and β isoforms, which differ in transcriptional activity and protein stability; STAT1β specifically enhances tumor immune surveillance by promoting CD8+ T-cell infiltration and suppressing M2 macrophage polarization in ovarian cancer^[4]. In disease models, aberrant STAT1 activation contributes to epithelial ovarian cancer progression, airway inflammation, and spinal cord injury, while targeted inhibition of STAT1 reduces apoptosis and inflammatory responses^[5][6][7]. Compared with other STAT family members, STAT1 exhibits unique regulatory interactions, such as selective inhibition by PIAS1 and differential phosphorylation at Y701 and S727, which modulate both canonical and non-canonical pathways^[1][3]. Small-molecule inhibitors and agonists, including fostamatinib, MK256, and 15dPGJ2, have been shown to modulate STAT1 activity in vitro and in vivo, offering tools for experimental intervention and potential therapeutic applications^[8][9][2]. These findings position STAT1 as a key regulator of immune and stress responses, distinct from related isoforms, and a targetable node for experimental and clinical studies.